CJC-1293: Evidence, Mechanism, Dosing & Legal Status

CJC-1293 is a synthetic growth-hormone-releasing hormone (GHRH, or "GRF") analog that belongs to the original ConjuChem albumin-binding bioconjugate series — the same R&D program that yielded the far better-known CJC-1295.1 Its popularity in the research-chemical marketplace rests almost entirely on claims borrowed from its sibling. This monograph separates what is actually known about CJC-1293 from what is merely marketed.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. CJC-1293 is not an FDA-approved drug; it is sold only as a "research chemical, not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in vendor and anecdotal sources for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is CJC-1293 and how does it work?

In the foundational ConjuChem work, three maleimido derivatives of human growth-hormone-releasing factor hGRF(1-29) were synthesized and conjugated to human serum albumin to test an "in-vivo bioconjugation" half-life-extension strategy: a reactive maleimido group on the peptide forms a covalent bond to the free thiol of Cys34 on circulating albumin, letting the peptide hitchhike on albumin's roughly 19-day serum residence.1 The three candidates were CJC-1288, CJC-1293 and CJC-1295; the tetrasubstituted CJC-1295 was identified as the best compound and carried forward, while CJC-1293 was effectively dropped.1 The primary paper is openly indexed at academic.oup.com.

Secondary summaries describe the series as a substitution ladder: CJC-1288 is the base bioconjugate (no backbone substitution); CJC-1293 is CJC-1288 plus a single D-Ala-2 substitution (the change that blocks dipeptidyl-peptidase-IV cleavage of the GHRH N-terminus); and CJC-1295 is the fully tetrasubstituted (positions 2, 8, 15, 27) analog.1 That exact per-position assignment for CJC-1293 comes from secondary aggregations of the paywalled full paper, not a primary source this monograph could verify line-by-line, so treat the specific structure as probable but not independently confirmed. What is solid is that CJC-1293 is a Drug Affinity Complex (albumin-binding) GRF analog, meaning its native design intent was long-acting, not short-acting.

The mechanism, by class, is GHRH-receptor agonism. Like all GHRH analogs, CJC-1293 is designed to bind the GHRH receptor, a Gs-coupled receptor on anterior-pituitary somatotrophs; activation raises intracellular cAMP and drives synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1.112 No published human or animal pharmacokinetics exist for CJC-1293 by name; by its albumin-binding design it would be expected to behave toward the long-acting end, like CJC-1295, whose albumin-bound species persisted in plasma beyond 72 hours in rats.2

What is the evidence by indication?

The bottom line up front: there are no studies of CJC-1293 as a stand-alone agent for any indication in humans or in published, named animal models. Every row below is therefore inference from the CJC-1295 family, and CJC-1293 is graded D across the board.

The only mechanistic "indication" with any human signal in the family is GH/IGF-1 stimulation — and that signal belongs to CJC-1295, not CJC-1293. In a randomized, double-blind, placebo-controlled ascending-dose study in healthy adults aged 21 to 61, single subcutaneous CJC-1295 doses of 30, 60, 125 and 250 micrograms per kilogram raised mean plasma GH 2- to 10-fold for at least 6 days and IGF-1 1.5- to 3-fold for 9 to 11 days, while preserving pulsatile secretion; injection-site reactions occurred in roughly 80% of subjects.2 This is human evidence for CJC-1295, and even for CJC-1295 it is small, early-phase and surrogate-endpoint data — grade B at best. A preclinical anchor showed once-daily CJC-1295 normalized growth in the GHRH-knockout mouse, confirming on-target agonism for the lead compound; no equivalent study names CJC-1293.3

For body composition, ConjuChem advanced CJC-1295 — not CJC-1293 — into a Phase 2 program in HIV-associated lipodystrophy and GH-axis indications. That program was discontinued after a participant death, which the attending physician attributed to pre-existing coronary disease judged unrelated to the drug, but development ended as a precaution and the compound was effectively abandoned.48 CJC-1293 was never developed this far. The muscle-gain, fat-loss, anti-aging, recovery and sleep claims attached to CJC-1293 in the consumer market have no controlled human support whatsoever.13

What doses appear in the literature, and how safe is it?

Reported strictly as information, not a protocol. No legitimate clinical dosing exists for CJC-1293 because it was never clinically developed under its own name. Consumer pages describe roughly 100 to 200 micrograms per subcutaneous injection, framed as needing more frequent administration than CJC-1295 — an unverified marketing claim (grade D) that is internally inconsistent with the molecule's long-acting DAC design.13 Clinical-trial dosing exists only for the sibling CJC-1295, where single subcutaneous doses of 30 to 250 micrograms per kilogram were studied and a roughly once-weekly cadence followed from its 6- to 8-day half-life; those numbers are not transferable to CJC-1293 as evidence.2

There is no CJC-1293-specific safety dataset, so all safety expectations come from the class. The dominant adverse event for CJC-1295 was injection-site reactions (around 80% of subjects), along with flushing, headache and transient fluid retention — the classic GH/IGF-1-axis effects.2 The development-ending death in the CJC-1295 Phase 2 program (attributed to pre-existing coronary disease) is part of why the FDA later flagged this class for heart-related concerns.48 The most important theoretical risk is mechanistic: sustained IGF-1 elevation is a plausible mitogenic, tumor-promotion concern because IGF-1 is a growth factor, alongside insulin-resistance, fluid-retention, arthralgia and carpal-tunnel-type concerns, plus the impurity and immunogenicity hazards specific to non-pharmaceutical research-chemical peptides.87 From a functional, root-cause lens, pharmacologically forcing the GH/IGF-1 axis does nothing to address why the axis is low (sleep debt, chronic stress, insulin resistance, undernutrition, inflammation) and carries the mitogenic downside without a validated benefit. Active or prior malignancy, pregnancy, lactation, pediatric use and uncontrolled endocrine disease are all class precautions.

What is the FDA and WADA status in 2026?

CJC-1293 has no FDA approval for any indication and is not a named bulks-list substance. The FDA's compounding-bulk-substance actions in this area targeted the CJC-1295 family, not CJC-1293 by name: CJC-1295 was placed in 503A Category 2 in September 2023, then removed in September 2024 after the nominators withdrew their nominations amid litigation.107 A December 2024 Pharmacy Compounding Advisory Committee review voted against adding the CJC-1295 bulk substances to the 503A list, citing insufficient human safety data and a lack of reproducible efficacy.911 CJC-1293 was not part of that docket at all, meaning it has even less of a path to legitimate compounded access than CJC-1295. It is sold online only as a research reagent explicitly labeled not for human consumption, outside FDA quality oversight.13

For athletes the picture is unambiguous. CJC-1293 is explicitly named on the WADA Prohibited List under category S2.2 (Growth Hormone Releasing Factors), alongside CJC-1295, sermorelin and tesamorelin; the 2026 list took effect on January 1, 2026, and these substances are banned both in and out of competition with no performance Therapeutic Use Exemption pathway.56 GHRH analogs in this class are detectable in anti-doping testing.12 CJC-1293 is not a DEA-controlled substance; the legality of human use is governed by FDA drug law as an unapproved new drug, not the Controlled Substances Act.

Bottom line. CJC-1293 is a thin-evidence curiosity — an abandoned intermediate whose every marketed benefit is borrowed from CJC-1295 and unproven for CJC-1293 itself. Anyone genuinely researching this molecule should default to the deeper CJC-1295 record, where what little real human evidence in this class actually lives, and treat CJC-1293's marketing copy with skepticism. Regulatory facts here are current as of June 2026 and should be re-verified after any subsequent PCAC or WADA updates.